These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33048300)

  • 1. Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
    Atal S; Fatima Z; Balakrishnan S
    BioDrugs; 2020 Dec; 34(6):705-711. PubMed ID: 33048300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
    Loganathan S; Athalye SN; Joshi SR
    Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.
    Kumar S; De Souza R; Nadkar M; Guleria R; Trikha A; Joshi SR; Loganathan S; Vaidyanathan S; Marwah A; Athalye SN
    Expert Opin Biol Ther; 2021 May; 21(5):675-686. PubMed ID: 33835886
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
    Díaz Y; Ramos-Suzarte M; Martín Y; Calderón NA; Santiago W; Viñet O; La O Y; Oyarzábal JPA; Pérez Y; Lorenzo G; Cepeda M; Saavedra D; Mazorra Z; Estevez D; Lorenzo-Luaces P; Valenzuela C; Caballero A; Leon K; Crombet T; Hidalgo CJ
    Gerontology; 2020; 66(6):553-561. PubMed ID: 33105142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus shifts to antibody cocktails for COVID-19 cytokine storm.
    Harrison C
    Nat Biotechnol; 2020 Aug; 38(8):905-908. PubMed ID: 32760027
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.
    León López R; Fernández SC; Limia Pérez L; Romero Palacios A; Fernández-Roldán MC; Aguilar Alonso E; Pérez Camacho I; Rodriguez-Baño J; Merchante N; Olalla J; Esteban-Moreno MÁ; Santos M; Luque-Pineda A; Torre-Cisneros J
    BMJ Open; 2020 Nov; 10(11):e039951. PubMed ID: 33191263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center.
    Kumari P; Kumar A; Sinha C; Kumar A; Singh PK; Arun SK
    Indian J Crit Care Med; 2021 Apr; 25(4):467-469. PubMed ID: 34045817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Antibodies vs COVID-19: Eduardo Ojito-Magaz MS General Director, Molecular Immunology Center.
    Aguilar TL; Gorry C
    MEDICC Rev; 2021 Apr; 23(2):12. PubMed ID: 33974610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial.
    Kulkarni S; Fisk M; Kostapanos M; Banham-Hall E; Bond S; Hernan-Sancho E; Norton S; Cheriyan J; Cope A; Galloway J; Hall F; Jayne D; Wilkinson IB
    Trials; 2020 Jul; 21(1):626. PubMed ID: 32641154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial.
    Griffiths G; Fitzgerald R; Jaki T; Corkhill A; Marwood E; Reynolds H; Stanton L; Ewings S; Condie S; Wrixon E; Norton A; Radford M; Yeats S; Robertson J; Darby-Dowman R; Walker L; Khoo S;
    Trials; 2020 Jun; 21(1):544. PubMed ID: 32560744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
    Krupashankar DS; Dogra S; Kura M; Saraswat A; Budamakuntla L; Sumathy TK; Shah R; Gopal MG; Narayana Rao T; Srinivas CR; Bhat R; Shetty N; Manmohan G; Sai Krishna K; Padmaja D; Pratap DV; Garg V; Gupta S; Pandey N; Khopkar U; Montero E; Ramakrishnan MS; Nair P; Ganapathi PC
    J Am Acad Dermatol; 2014 Sep; 71(3):484-92. PubMed ID: 24703722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.
    Ghati N; Roy A; Bhatnagar S; Bhati S; Bhushan S; Mahendran M; Thakur A; Tiwari P; Dwivedi T; Mani K; Gupta R; Mohan A; Garg R; Saxena A; Guleria R; Deepti S
    Trials; 2020 Oct; 21(1):902. PubMed ID: 33126910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Repositioning for COVID-19.
    Benavides-Cordoba V
    Colomb Med (Cali); 2020 Jun; 51(2):e4279. PubMed ID: 33012890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
    Zhang Y; Zhong Y; Pan L; Dong J
    Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: an unexpected indication for anti-rheumatic therapies?
    Lucchino B; Di Franco M; Conti F
    Rheumatology (Oxford); 2020 Jun; 59(6):1200-1203. PubMed ID: 32374874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.